首页 > 最新文献

BJUI compass最新文献

英文 中文
Immune checkpoint inhibitors in high-grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation 免疫检查点抑制剂治疗高级别上尿路上皮癌:强调器官保护的范式转变
Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-03-03 DOI: 10.1002/bco2.335
Mahmoud Khalil, Andrew Fishman, Anna Komorowski, Israel Franco, Michael Grasso III

Objective

The aim was to evaluate the role of immune check point inhibitors (ICIs) in patients with high-grade upper tract urothelial carcinoma (UTUC) who are managed endoscopically when nephroureterectomy (NU) is not feasible, such as in patients who are either not candidates for NU or decline extirpative surgery.

Methods

All patients diagnosed with high-grade UTUC and managed endoscopically between January 1996 and August 2022 were included in the study. Subsequently, patients were categorised based on their use of ICIs into group 1 (patients who did not receive ICIs) and group 2 (patients who received ICIs). Survival outcomes were assessed using Kaplan–Meier analysis, while a multivariable regression model was employed to analyse the impact of clinical characteristics on survival.

Results

A total of 29 patients were enrolled, with 14 in group 1 and 15 in group 2. Both groups exhibited similar demographic and disease characteristics, including multifocality, laterality and initial tumour size. The median follow-up period was 29.2 months. Notably, group 2 demonstrated significantly enhanced overall and metastasis-free survival rates compared to group 1. At 47.8 months, the overall survival rate was 0% (all patients died) in group 1, whereas it was 85.7% in group 2. Similarly, the metastasis-free survival rate was 0% (all patients had metastatic disease) in group 1 at 40.6 months, whereas it reached 78.0% in group 2. The multivariable analysis indicated a correlation between ICI usage and improved survival outcomes, with a hazard ratio of 0.002.

Conclusion

Utilisation of adjuvant ICIs in the setting of endoscopically treated patients with high-grade UTUC is associated with significantly improved survival rates. ICIs should be considered in this patient population, however, more studies with larger sample size are warranted.

目的 评估免疫检查点抑制剂(ICIs)在肾切除术(NU)不可行时通过内镜治疗的高级别上尿路上皮癌(UTUC)患者中的作用,例如在不适合接受肾切除术或拒绝根治性手术的患者中的作用。 方法 将 1996 年 1 月至 2022 年 8 月期间确诊为高级别 UTUC 并接受内镜治疗的所有患者纳入研究。随后,根据使用 ICIs 的情况将患者分为第 1 组(未使用 ICIs 的患者)和第 2 组(使用 ICIs 的患者)。采用卡普兰-梅耶尔分析法评估存活率,同时采用多变量回归模型分析临床特征对存活率的影响。 结果 两组患者的人口统计学特征和疾病特征相似,包括多灶性、侧位性和初始肿瘤大小。中位随访时间为 29.2 个月。值得注意的是,与第一组相比,第二组的总生存率和无转移生存率明显提高。47.8个月时,第一组的总生存率为0%(所有患者均死亡),而第二组的总生存率为85.7%。同样,40.6个月时,第一组的无转移生存率为0%(所有患者均有转移性疾病),而第二组的无转移生存率达到78.0%。 结论 经内镜治疗的高级别 UTUC 患者使用 ICIs 辅助治疗可显著提高生存率。这类患者应考虑使用 ICIs,但还需要更多样本量更大的研究。
{"title":"Immune checkpoint inhibitors in high-grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation","authors":"Mahmoud Khalil,&nbsp;Andrew Fishman,&nbsp;Anna Komorowski,&nbsp;Israel Franco,&nbsp;Michael Grasso III","doi":"10.1002/bco2.335","DOIUrl":"https://doi.org/10.1002/bco2.335","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The aim was to evaluate the role of immune check point inhibitors (ICIs) in patients with high-grade upper tract urothelial carcinoma (UTUC) who are managed endoscopically when nephroureterectomy (NU) is not feasible, such as in patients who are either not candidates for NU or decline extirpative surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>All patients diagnosed with high-grade UTUC and managed endoscopically between January 1996 and August 2022 were included in the study. Subsequently, patients were categorised based on their use of ICIs into group 1 (patients who did not receive ICIs) and group 2 (patients who received ICIs). Survival outcomes were assessed using Kaplan–Meier analysis, while a multivariable regression model was employed to analyse the impact of clinical characteristics on survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 29 patients were enrolled, with 14 in group 1 and 15 in group 2. Both groups exhibited similar demographic and disease characteristics, including multifocality, laterality and initial tumour size. The median follow-up period was 29.2 months. Notably, group 2 demonstrated significantly enhanced overall and metastasis-free survival rates compared to group 1. At 47.8 months, the overall survival rate was 0% (all patients died) in group 1, whereas it was 85.7% in group 2. Similarly, the metastasis-free survival rate was 0% (all patients had metastatic disease) in group 1 at 40.6 months, whereas it reached 78.0% in group 2. The multivariable analysis indicated a correlation between ICI usage and improved survival outcomes, with a hazard ratio of 0.002.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Utilisation of adjuvant ICIs in the setting of endoscopically treated patients with high-grade UTUC is associated with significantly improved survival rates. ICIs should be considered in this patient population, however, more studies with larger sample size are warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 5","pages":"490-496"},"PeriodicalIF":0.0,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.335","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140919309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acu-URO17 is a highly sensitive and specific bladder cancer biomarker Acu-URO17 是一种高度灵敏且特异的膀胱癌生物标记物
Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-02-29 DOI: 10.1002/bco2.338
Liwu Guo, Alexandra Cid, John Cucci, Brian Kunkel, Lisa Defeis, Michael Matthews

Objective

This study evaluates the efficacy of Acu-URO17, a highly sensitive and specific immunocytochemistry (ICC) test targeting Keratin 17, in comparison to urine cytology and UroVysion™ fluorescence in situ hybridization (FISH) for detecting bladder cancer cells in voided urine specimens.

Methods

Acupath conducted a large-scale comparison study using 2378 voided urine specimens. Acu-URO17, urine cytology and UroVysion™ FISH were performed on these specimens according to standardized protocols. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for Acu-URO17 in comparison to urine cytology and UroVysion™ FISH.

Results

In cases diagnosed with high-grade urothelial cancer via urine cytology, Acu-URO17 demonstrated a sensitivity of 96% and a specificity of 82%. When compared to UroVysion™ FISH results, Acu-URO17 exhibited a sensitivity of 97.1% and a specificity of 77.8%, surpassing the sensitivity of UroVysion™ FISH (57.1%). Notably, Acu-URO17 showed a high NPV of 99.9%, indicating its reliability in confirming negative urine cytology results and risk-stratifying atypical and suspicious cytology results.

Conclusion

The results of this large-scale prospective study support Acu-URO17 as a clinically relevant, non-invasive and cost-effective tool for detecting bladder cancer cells in voided urine specimens. Its high sensitivity, specificity and NPV make it a valuable adjunct to urine cytology and UroVysion™ FISH in the diagnosis and management of urothelial carcinoma (UC).

本研究评估了针对角蛋白 17 的高灵敏度和特异性免疫细胞化学(ICC)检验 Acu-URO17 与尿液细胞学和 UroVysion™ 荧光原位杂交(FISH)在检测排空尿液标本中的膀胱癌细胞方面的功效。Acu-URO17 、尿液细胞学和 UroVysion™ FISH 都是按照标准化方案对这些标本进行检测的。与尿液细胞学检查和 UroVysion™ FISH 相比,计算了 Acu-URO17 的灵敏度、特异性、阳性预测值 (PPV) 和阴性预测值 (NPV)。与 UroVysion™ FISH 结果相比,Acu-URO17 的灵敏度为 97.1%,特异性为 77.8%,超过了 UroVysion™ FISH 的灵敏度(57.1%)。值得注意的是,Acu-URO17 的 NPV 值高达 99.9%,这表明它在确认阴性尿液细胞学结果以及对不典型和可疑细胞学结果进行风险分级方面非常可靠。这项大规模前瞻性研究的结果表明,Acu-URO17 是检测排空尿液标本中膀胱癌细胞的一种临床相关、无创且经济有效的工具。它的高灵敏度、高特异性和高净现值使其成为尿液细胞学和 UroVysion™ FISH 诊断和治疗尿路上皮癌 (UC) 的重要辅助手段。
{"title":"Acu-URO17 is a highly sensitive and specific bladder cancer biomarker","authors":"Liwu Guo,&nbsp;Alexandra Cid,&nbsp;John Cucci,&nbsp;Brian Kunkel,&nbsp;Lisa Defeis,&nbsp;Michael Matthews","doi":"10.1002/bco2.338","DOIUrl":"10.1002/bco2.338","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study evaluates the efficacy of Acu-URO17, a highly sensitive and specific immunocytochemistry (ICC) test targeting Keratin 17, in comparison to urine cytology and UroVysion™ fluorescence in situ hybridization (FISH) for detecting bladder cancer cells in voided urine specimens.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Acupath conducted a large-scale comparison study using 2378 voided urine specimens. Acu-URO17, urine cytology and UroVysion™ FISH were performed on these specimens according to standardized protocols. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for Acu-URO17 in comparison to urine cytology and UroVysion™ FISH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In cases diagnosed with high-grade urothelial cancer via urine cytology, Acu-URO17 demonstrated a sensitivity of 96% and a specificity of 82%. When compared to UroVysion™ FISH results, Acu-URO17 exhibited a sensitivity of 97.1% and a specificity of 77.8%, surpassing the sensitivity of UroVysion™ FISH (57.1%). Notably, Acu-URO17 showed a high NPV of 99.9%, indicating its reliability in confirming negative urine cytology results and risk-stratifying atypical and suspicious cytology results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The results of this large-scale prospective study support Acu-URO17 as a clinically relevant, non-invasive and cost-effective tool for detecting bladder cancer cells in voided urine specimens. Its high sensitivity, specificity and NPV make it a valuable adjunct to urine cytology and UroVysion™ FISH in the diagnosis and management of urothelial carcinoma (UC).</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 5","pages":"497-501"},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.338","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140410018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racial and socioeconomic disparities in surgical care for post-prostate cancer treatment complications: A nationwide Medicare-based analysis 前列腺癌治疗后并发症手术护理中的种族和社会经济差异:基于医疗保险的全国性分析
Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-02-29 DOI: 10.1002/bco2.342
Oluwafolajimi Adesanya, Sirikan Rojanasarot, Alysha M. McGovern, Arthur L. Burnett

Objectives

To investigate the racial and socioeconomic (income) differences in receipt of and time to surgical care for urinary incontinence (UI) and erectile dysfunction (ED) occurring post-radical prostatectomy (RP) and/or radiation therapy (RT).

Materials and Methods

Utilizing the Medicare Standard Analytical Files (SAF), a retrospective cohort study was performed on data of patients diagnosed with prostate cancer (PCa) from 2015 to 2021. Patients who underwent RP and/or RT and who subsequently developed UI and/or ED were grouped into four cohorts: RP-ED, RP-UI, RT-ED and RT-UI. County-level median household income was cross-referenced with SAF county codes, classified into income quartiles, and used as a proxy for patient income status. The rate of surgical care was compared between groups using two-sample t-test and log-rank test. Cox proportional hazards modelling was used to determine covariate-adjusted impact of race on time to surgical care.

Results

The rate of surgical care was 6.8, 3.61 3.07, and 1.54 per 100 person-years for the RP-UI, RT-UI, RP-ED, and RT-ED cohorts, respectively. Cox proportional ‘time-to-surgical care’ regression analysis revealed that Black men were statistically more likely to receive ED surgical care (RP-ED AHR:1.79, 95% CI:1.49–2.17; RT-ED AHR:1.50, 95% CI:1.11–2.01), but less likely to receive UI surgical care (RP-UI AHR:0.80, 95% CI:0.67–0.96) than White men, in all cohorts except RT-UI. Surgical care was highest among Q1 (lowest income quartile) patients in all cohorts except RT-UI.

Conclusions

Surgical care for post-PCa treatment complications is low, and significantly impacted by racial and socioeconomic (income) differences. Prospective studies investigating the basis of these results would be insightful.

利用医疗保险标准分析档案(SAF),对 2015 年至 2021 年期间诊断为前列腺癌(PCa)的患者数据进行了一项回顾性队列研究。接受 RP 和/或 RT 术后出现 UI 和/或 ED 的患者被分为四个队列:RP-ED、RP-UI、RT-ED 和 RT-UI。将县级家庭收入中位数与 SAF 县级代码进行交叉比对,划分为收入四分位数,并将其作为患者收入状况的替代指标。使用双样本 t 检验和对数秩检验比较各组之间的手术治疗率。RP-UI、RT-UI、RP-ED 和 RT-ED 组群的手术治疗率分别为每 100 人年 6.8 例、3.61 例、3.07 例和 1.54 例。Cox比例 "手术治疗时间 "回归分析表明,在除RT-UI以外的所有队列中,黑人男性接受ED手术治疗的可能性高于白人男性(RP-ED AHR:1.79,95% CI:1.49-2.17;RT-ED AHR:1.50,95% CI:1.11-2.01),但接受UI手术治疗的可能性低于白人男性(RP-UI AHR:0.80,95% CI:0.67-0.96)。在除 RT-UI 以外的所有队列中,Q1(最低收入四分位数)患者的手术治疗率最高。对这些结果的基础进行前瞻性研究将很有启发。
{"title":"Racial and socioeconomic disparities in surgical care for post-prostate cancer treatment complications: A nationwide Medicare-based analysis","authors":"Oluwafolajimi Adesanya,&nbsp;Sirikan Rojanasarot,&nbsp;Alysha M. McGovern,&nbsp;Arthur L. Burnett","doi":"10.1002/bco2.342","DOIUrl":"10.1002/bco2.342","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To investigate the racial and socioeconomic (income) differences in receipt of and time to surgical care for urinary incontinence (UI) and erectile dysfunction (ED) occurring post-radical prostatectomy (RP) and/or radiation therapy (RT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Utilizing the Medicare Standard Analytical Files (SAF), a retrospective cohort study was performed on data of patients diagnosed with prostate cancer (PCa) from 2015 to 2021. Patients who underwent RP and/or RT and who subsequently developed UI and/or ED were grouped into four cohorts: RP-ED, RP-UI, RT-ED and RT-UI. County-level median household income was cross-referenced with SAF county codes, classified into income quartiles, and used as a proxy for patient income status. The rate of surgical care was compared between groups using two-sample t-test and log-rank test. Cox proportional hazards modelling was used to determine covariate-adjusted impact of race on time to surgical care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The rate of surgical care was 6.8, 3.61 3.07, and 1.54 per 100 person-years for the RP-UI, RT-UI, RP-ED, and RT-ED cohorts, respectively. Cox proportional <i>‘time-to-surgical care’</i> regression analysis revealed that Black men were statistically more likely to receive ED surgical care (RP-ED AHR:1.79, 95% CI:1.49–2.17; RT-ED AHR:1.50, 95% CI:1.11–2.01), but less likely to receive UI surgical care (RP-UI AHR:0.80, 95% CI:0.67–0.96) than White men, in all cohorts except RT-UI. Surgical care was highest among Q1 (lowest income quartile) patients in all cohorts except RT-UI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Surgical care for post-PCa treatment complications is low, and significantly impacted by racial and socioeconomic (income) differences. Prospective studies investigating the basis of these results would be insightful.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 6","pages":"564-575"},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.342","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140412936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cumulative incidence and risk factors for recurrence of upper tract urothelial carcinoma in patients undergoing radical cystectomy 接受根治性膀胱切除术患者上尿路上皮癌的累积发病率和复发风险因素
Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-02-29 DOI: 10.1002/bco2.336
Ryo Yamashita, Masafumi Nakamura, Akifumi Notsu, Koiku Asakura, Kimitsugu Usui, Yuma Sakura, Hideo Shinsaka, Masato Matsuzaki, Takashi Sugino, Ryuichi Mizuno, Masashi Niwakawa, Mototsugu Oya

Objectives

This study aimed to evaluate the cumulative incidence of upper tract urothelial carcinoma (UTUC) recurrence and identify its risk factors in patients who underwent radical cystectomy (RC).

Patients and methods

We performed RC on 385 patients between September 2002 and February 2020. After excluding 20 patients—13 with simultaneous nephroureterectomy, 6 with distal ureteral stump positivity and 1 with urachal cancer—365 patients were included in the analysis. To predict UTUC recurrence, we examined the cancer extension pattern in cystectomy specimens and categorized them into three types: cancer located only in the bladder (bladder-only type), cancer extending to the urethra or distal ureter (one-extension type) and cancer extending to both the urethra and distal ureter (both-extension type). We determined hazard ratios for UTUC recurrence for each covariate, including this cancer extension pattern.

Results

Of the 365 patients, 60% had the bladder-only type, 30% had the one-extension type and 10% had the both-extension type. During a median follow-up period of 72 months for survivors, UTUC recurred in 25 of the 365 patients, with cumulative incidences of 3.7% at 5 years and 8.3% at 10 years. The median interval from cystectomy to recurrence was 65 months (interquartile range: 36–92 months). In the multivariate analysis, the extension pattern was a significant predictor of UTUC recurrence. The hazard ratios for UTUC recurrence were 3.12 (95% confidence interval [CI] = 1.15–8.43, p = 0.025) for the one-extension type and 5.96 (95% CI = 1.98–17.91, p = 0.001) for the both-extension type compared with the bladder-only type.

Conclusions

The cancer extension pattern in cystectomy specimens is predictive of UTUC recurrence. A more extensive cancer extension in cystectomy specimens elevates the risk of subsequent UTUC recurrence. Intensive long-term monitoring is essential, particularly for patients with the both-extension type.

本研究旨在评估接受根治性膀胱切除术(RC)患者的上尿路上皮癌(UTUC)复发累积发生率,并确定其风险因素。我们在 2002 年 9 月至 2020 年 2 月期间对 385 名患者进行了根治性膀胱切除术,在排除了 20 名患者(13 名同时进行了肾切除术,6 名输尿管远端残端阳性,1 名泌尿道癌患者)后,365 名患者纳入了分析。为了预测UTUC的复发,我们检查了膀胱切除标本中癌症的延伸模式,并将其分为三种类型:仅位于膀胱的癌症(仅膀胱型)、延伸至尿道或输尿管远端的癌症(单延伸型)以及同时延伸至尿道和输尿管远端的癌症(双延伸型)。在365名患者中,60%为单纯膀胱型,30%为单侧延伸型,10%为双侧延伸型。在幸存者72个月的中位随访期间,365名患者中有25人UTUC复发,5年和10年的累计发病率分别为3.7%和8.3%。从膀胱切除术到复发的中位间隔为 65 个月(四分位数间距:36-92 个月)。在多变量分析中,延伸模式是UTUC复发的重要预测因素。与纯膀胱型相比,单延伸型的UTUC复发危险比为3.12(95%置信区间[CI] = 1.15-8.43,p = 0.025),双延伸型的UTUC复发危险比为5.96(95%置信区间[CI] = 1.98-17.91,p = 0.001)。膀胱切除标本中的癌症扩展范围越广,UTUC随后复发的风险就越高。加强长期监测至关重要,尤其是对双侧延伸型患者。
{"title":"Cumulative incidence and risk factors for recurrence of upper tract urothelial carcinoma in patients undergoing radical cystectomy","authors":"Ryo Yamashita,&nbsp;Masafumi Nakamura,&nbsp;Akifumi Notsu,&nbsp;Koiku Asakura,&nbsp;Kimitsugu Usui,&nbsp;Yuma Sakura,&nbsp;Hideo Shinsaka,&nbsp;Masato Matsuzaki,&nbsp;Takashi Sugino,&nbsp;Ryuichi Mizuno,&nbsp;Masashi Niwakawa,&nbsp;Mototsugu Oya","doi":"10.1002/bco2.336","DOIUrl":"10.1002/bco2.336","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to evaluate the cumulative incidence of upper tract urothelial carcinoma (UTUC) recurrence and identify its risk factors in patients who underwent radical cystectomy (RC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and methods</h3>\u0000 \u0000 <p>We performed RC on 385 patients between September 2002 and February 2020. After excluding 20 patients—13 with simultaneous nephroureterectomy, 6 with distal ureteral stump positivity and 1 with urachal cancer—365 patients were included in the analysis. To predict UTUC recurrence, we examined the cancer extension pattern in cystectomy specimens and categorized them into three types: cancer located only in the bladder (bladder-only type), cancer extending to the urethra or distal ureter (one-extension type) and cancer extending to both the urethra and distal ureter (both-extension type). We determined hazard ratios for UTUC recurrence for each covariate, including this cancer extension pattern.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 365 patients, 60% had the bladder-only type, 30% had the one-extension type and 10% had the both-extension type. During a median follow-up period of 72 months for survivors, UTUC recurred in 25 of the 365 patients, with cumulative incidences of 3.7% at 5 years and 8.3% at 10 years. The median interval from cystectomy to recurrence was 65 months (interquartile range: 36–92 months). In the multivariate analysis, the extension pattern was a significant predictor of UTUC recurrence. The hazard ratios for UTUC recurrence were 3.12 (95% confidence interval [CI] = 1.15–8.43, <i>p</i> = 0.025) for the one-extension type and 5.96 (95% CI = 1.98–17.91, <i>p</i> = 0.001) for the both-extension type compared with the bladder-only type.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The cancer extension pattern in cystectomy specimens is predictive of UTUC recurrence. A more extensive cancer extension in cystectomy specimens elevates the risk of subsequent UTUC recurrence. Intensive long-term monitoring is essential, particularly for patients with the both-extension type.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 5","pages":"483-489"},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.336","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140415955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review of the patient reported outcomes that affect patients with muscle invasive bladder cancer after radical cystectomy and urinary diversion 患者报告的影响肌层浸润性膀胱癌患者根治性膀胱切除术和尿路转流术后疗效的系统性综述
Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-02-27 DOI: 10.1002/bco2.339
John Lahoud, Manish I. Patel, Sayeda Naher, Rebecca Mercieca-Bebber

Objectives

To determine the functional domains and symptom scales that affect patients most following radical cystectomy (RC) and urinary diversion (UD), and if a single instrument (or combination) adequately captures these bothersome symptoms. It is unclear whether current patient reported outcome (PRO) instruments that have been used to assess quality of life in patients following RC and UD adequately cover the most bothersome symptoms affecting patients.

Materials and methods

A systematic search of MEDLINE, EMBASE, PubMed, Cinahl and Cochrane was conducted from January 2000 to May 2023 for original articles of patients who had RC and UD since 2000 for muscle invasive bladder cancer. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) process was followed. Extracted data included the PRO measures used, domains reported and scores in the first 12 months post-surgery (short-term) and after 12 months (long-term). A conservative threshold of <70 for functional domains and >30 for symptom domains was used to determine which PRO domains were potentially concerning to patients in each study. Quality assessment was performed using the QUALSYST appraisal tool.

Results

Thirty-five studies met the inclusion criteria, including a total of eight unique PRO instruments. The main findings indicated that physical function was the most concerning PRO for patients with both neobladder (NB) and ileal conduit (IC) in the short and long term. Additionally, bowel, urinary and sexual bother were concerning symptoms for patients with NB in the long-term, but only in the short-term for those with IC.

Conclusions

The main issues are adequately addressed using the combination of EORTC QLQ-C30 and QLQ-BLM30 instruments.

目的:确定根治性膀胱切除术(RC)和尿路改道术(UD)后对患者影响最大的功能领域和症状量表,以及单一工具(或组合工具)是否能充分捕捉到这些令人烦恼的症状。从 2000 年 1 月到 2023 年 5 月,我们对 MEDLINE、EMBASE、PubMed、Cinahl 和 Cochrane 进行了系统检索,以获取 2000 年以来因肌浸润性膀胱癌而接受根治性膀胱切除术和尿路转流术的患者的原始文章。研究遵循了系统综述和元分析首选报告项目(PRISMA)流程。提取的数据包括所使用的PRO测量方法、报告的领域以及术后头12个月(短期)和12个月后(长期)的得分。在每项研究中,症状域的保守阈值为 30,以确定哪些 PRO 域可能与患者有关。共有 35 项研究符合纳入标准,其中包括 8 种独特的 PRO 工具。主要研究结果表明,身体功能是新膀胱(NB)和回肠导管(IC)患者在短期和长期内最关心的PRO指标。此外,肠道、泌尿和性困扰也是新膀胱(NB)患者长期关注的症状,但对于回肠导管(IC)患者而言,这些症状只在短期内出现。
{"title":"A systematic review of the patient reported outcomes that affect patients with muscle invasive bladder cancer after radical cystectomy and urinary diversion","authors":"John Lahoud,&nbsp;Manish I. Patel,&nbsp;Sayeda Naher,&nbsp;Rebecca Mercieca-Bebber","doi":"10.1002/bco2.339","DOIUrl":"10.1002/bco2.339","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To determine the functional domains and symptom scales that affect patients most following radical cystectomy (RC) and urinary diversion (UD), and if a single instrument (or combination) adequately captures these bothersome symptoms. It is unclear whether current patient reported outcome (PRO) instruments that have been used to assess quality of life in patients following RC and UD adequately cover the most bothersome symptoms affecting patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>A systematic search of MEDLINE, EMBASE, PubMed, Cinahl and Cochrane was conducted from January 2000 to May 2023 for original articles of patients who had RC and UD since 2000 for muscle invasive bladder cancer. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) process was followed. Extracted data included the PRO measures used, domains reported and scores in the first 12 months post-surgery (short-term) and after 12 months (long-term). A conservative threshold of &lt;70 for functional domains and &gt;30 for symptom domains was used to determine which PRO domains were potentially concerning to patients in each study. Quality assessment was performed using the QUALSYST appraisal tool.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-five studies met the inclusion criteria, including a total of eight unique PRO instruments. The main findings indicated that physical function was the most concerning PRO for patients with both neobladder (NB) and ileal conduit (IC) in the short and long term. Additionally, bowel, urinary and sexual bother were concerning symptoms for patients with NB in the long-term, but only in the short-term for those with IC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The main issues are adequately addressed using the combination of EORTC QLQ-C30 and QLQ-BLM30 instruments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 6","pages":"524-540"},"PeriodicalIF":0.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.339","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140425144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malignant upper urinary tract obstruction in cancer patients: A systematic review 癌症患者的恶性上尿路梗阻:系统回顾
Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-02-27 DOI: 10.1002/bco2.340
Max Shah, Francesca Blest, James Blackmur, Alexander Laird, Shoba Dawson, Jonathan Aning

Objective

To systematically summarise the current clinical evidence for de novo malignant upper urinary tract obstruction treatment with a focus on standards of reporting, patient outcomes and future research needs.

Methods

This review protocol was published via PROSPERO (CRD42022341588). OVID MEDLINE (R), EMBASE, Cochrane Central Register of Controlled Trials—CENTRAL were searched up to June 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses. Prospective and retrospective studies were included.

Results

Of 941 articles identified, 82 with 8796 patients were eligible for inclusion.

Most studies in the published literature are retrospective and investigate heterogenous malignancies. Percutaneous nephrostomy and ureteric stenting are the most studied interventions. Few studies describe the outcomes from no intervention or investigate patient perspectives. Overall reported median survival after intervention was around 11.7 months. A lack of standardised reporting of outcomes was evident.

Conclusions

Malignant upper urinary tract obstruction is an important clinical condition affecting patients globally. Overall survival after intervention appears poor however the current evidence base has significant limitations due to studies of low methodological quality and the lack of a standardised framework for reporting outcomes.

We have provided a pragmatic framework for future studies based on the review to ensure a uniform methodology is utilised moving forward.

系统总结目前治疗新发恶性上尿路梗阻的临床证据,重点关注报告标准、患者预后和未来研究需求。本综述方案通过 PROSPERO (CRD42022341588) 发布。根据 "系统综述和元分析首选报告项目",检索了截至 2022 年 6 月的 OVID MEDLINE (R)、EMBASE 和 Cochrane Central Register of Controlled Trials-CENTRAL。在已发现的941篇文章中,有82篇共8796名患者符合纳入条件。经皮肾造瘘术和输尿管支架植入术是研究最多的干预措施。很少有研究描述未进行干预的结果或调查患者的观点。总体报告显示,介入治疗后的中位生存期约为 11.7 个月。恶性上尿路梗阻是影响全球患者的重要临床症状。干预后的总体存活率似乎不高,但由于研究方法质量不高以及缺乏标准化的结果报告框架,目前的证据基础存在很大的局限性。我们在综述的基础上为未来的研究提供了一个务实的框架,以确保今后采用统一的方法。
{"title":"Malignant upper urinary tract obstruction in cancer patients: A systematic review","authors":"Max Shah,&nbsp;Francesca Blest,&nbsp;James Blackmur,&nbsp;Alexander Laird,&nbsp;Shoba Dawson,&nbsp;Jonathan Aning","doi":"10.1002/bco2.340","DOIUrl":"10.1002/bco2.340","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To systematically summarise the current clinical evidence for de novo malignant upper urinary tract obstruction treatment with a focus on standards of reporting, patient outcomes and future research needs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This review protocol was published via PROSPERO (CRD42022341588). OVID MEDLINE (R), EMBASE, Cochrane Central Register of Controlled Trials—CENTRAL were searched up to June 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses. Prospective and retrospective studies were included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 941 articles identified, 82 with 8796 patients were eligible for inclusion.</p>\u0000 \u0000 <p>Most studies in the published literature are retrospective and investigate heterogenous malignancies. Percutaneous nephrostomy and ureteric stenting are the most studied interventions. Few studies describe the outcomes from no intervention or investigate patient perspectives. Overall reported median survival after intervention was around 11.7 months. A lack of standardised reporting of outcomes was evident.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Malignant upper urinary tract obstruction is an important clinical condition affecting patients globally. Overall survival after intervention appears poor however the current evidence base has significant limitations due to studies of low methodological quality and the lack of a standardised framework for reporting outcomes.</p>\u0000 \u0000 <p>We have provided a pragmatic framework for future studies based on the review to ensure a uniform methodology is utilised moving forward.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 5","pages":"405-416"},"PeriodicalIF":0.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.340","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140425374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A preoperative magnetic resonance imaging can aid in staging and treatment choice for upper tract urothelial carcinoma 术前磁共振成像有助于上尿路上皮癌的分期和治疗选择
Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-02-24 DOI: 10.1002/bco2.337
Bjarte Almås, Lars Anders Rokne Reisæter, Carl Erik Markhus, Karin Margrethe Hjelle, Astrid Børretzen, Christian Beisland

Objectives

The aim was to investigate the predictive abilities of a preoperative diffusion-weighted MRI (dwMRI) among patients with surgically treated upper tract urothelial carcinoma (UTUC).

Materials and methods

Written consent was obtained from all participants in this prospective and ethically approved study. Thirty-five UTUC patients treated with radical surgery were examined with a preoperative dwMRI and prospectively included during 2017–2022. Two radiologists examined the CT scans and dwMRIs for radiological stage, and the apparent diffusion coefficient (ADC) in the tumours at the dwMRI was registered. The radiologists were blinded for patient history, final histopathology and the readings of the other radiologist. The radiological variables were analysed regarding their abilities to predict muscle-invasive disease (MID, T2–T4) and tumour grade at final pathology after radical surgery. The predictive abilities were assessed using chi-square tests, Student's t-test and calculating the area under the curve in a receiver operating characteristic (ROC) curve. Correlation between the two radiologists was quantified calculating the intra-class correlation coefficient. P-values <0.05 were considered statistically significant.

Results

Mean age was 72 years, 20 had high-grade tumour, and 13 patients had MID. The ADC values at the dwMRI were significantly lower among patients with MID compared to patients with non-muscle-invasive disease (930 vs 1189, p = <0.001). The area under the ROC curve (AUC) in an ROC curve to predict MID was 0.88 (CI 0.77–0.99, p = <0.001). The ADC values were significantly lower among patients with high-grade tumours compared to low-grade tumours (1005 vs 1210, p = 0.002). The correlation of the ADC measurements between the two radiologists was of 0.93 (CI 0.85–0.96, p < 0.001).

Conclusion

Tumour ADC at the MRI emerges as a potential biomarker for aggressive disease. The results are promising but should be validated in a larger, multicentre study.

该研究旨在探讨术前弥散加权磁共振成像(dwMRI)对接受手术治疗的上尿路上皮癌(UTUC)患者的预测能力。35名接受根治性手术治疗的UTUC患者在术前接受了dwMRI检查,并在2017-2022年间进行了前瞻性纳入。两名放射科医生检查了CT扫描和dwMRI的放射分期,并登记了dwMRI中肿瘤的表观弥散系数(ADC)。放射科医生对患者病史、最终组织病理学和另一名放射科医生的读数均为盲法。分析了放射学变量预测肌肉浸润性疾病(MID,T2-T4)和根治术后最终病理学检查肿瘤分级的能力。预测能力通过卡方检验、学生 t 检验和计算接收器操作特征曲线(ROC)的曲线下面积进行评估。两名放射医师之间的相关性通过计算类内相关系数进行量化。平均年龄为 72 岁,20 人患有高级别肿瘤,13 人患有 MID。与非肌层浸润性疾病患者相比,MID 患者的 dwMRI ADC 值明显较低(930 vs 1189,P = <0.001)。预测 MID 的 ROC 曲线下面积 (AUC) 为 0.88 (CI 0.77-0.99, p = <0.001)。高级别肿瘤患者的 ADC 值明显低于低级别肿瘤患者(1005 vs 1210,p = 0.002)。两位放射科医生的 ADC 测量值相关性为 0.93(CI 0.85-0.96,p < 0.001)。这些结果很有希望,但还应在更大规模的多中心研究中加以验证。
{"title":"A preoperative magnetic resonance imaging can aid in staging and treatment choice for upper tract urothelial carcinoma","authors":"Bjarte Almås,&nbsp;Lars Anders Rokne Reisæter,&nbsp;Carl Erik Markhus,&nbsp;Karin Margrethe Hjelle,&nbsp;Astrid Børretzen,&nbsp;Christian Beisland","doi":"10.1002/bco2.337","DOIUrl":"10.1002/bco2.337","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim was to investigate the predictive abilities of a preoperative diffusion-weighted MRI (dwMRI) among patients with surgically treated upper tract urothelial carcinoma (UTUC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>Written consent was obtained from all participants in this prospective and ethically approved study. Thirty-five UTUC patients treated with radical surgery were examined with a preoperative dwMRI and prospectively included during 2017–2022. Two radiologists examined the CT scans and dwMRIs for radiological stage, and the apparent diffusion coefficient (ADC) in the tumours at the dwMRI was registered. The radiologists were blinded for patient history, final histopathology and the readings of the other radiologist. The radiological variables were analysed regarding their abilities to predict muscle-invasive disease (MID, T2–T4) and tumour grade at final pathology after radical surgery. The predictive abilities were assessed using chi-square tests, Student's <i>t</i>-test and calculating the area under the curve in a receiver operating characteristic (ROC) curve. Correlation between the two radiologists was quantified calculating the intra-class correlation coefficient. <i>P</i>-values &lt;0.05 were considered statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mean age was 72 years, 20 had high-grade tumour, and 13 patients had MID. The ADC values at the dwMRI were significantly lower among patients with MID compared to patients with non-muscle-invasive disease (930 vs 1189, <i>p</i> = &lt;0.001). The area under the ROC curve (AUC) in an ROC curve to predict MID was 0.88 (CI 0.77–0.99, <i>p</i> = &lt;0.001). The ADC values were significantly lower among patients with high-grade tumours compared to low-grade tumours (1005 vs 1210, <i>p</i> = 0.002). The correlation of the ADC measurements between the two radiologists was of 0.93 (CI 0.85–0.96, <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Tumour ADC at the MRI emerges as a potential biomarker for aggressive disease. The results are promising but should be validated in a larger, multicentre study.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 5","pages":"476-482"},"PeriodicalIF":0.0,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.337","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140434754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association between pre-diagnostic levels of psychological distress and adverse effects after radical prostatectomy 诊断前的心理压力水平与根治性前列腺切除术后不良反应之间的关系
Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-02-24 DOI: 10.1002/bco2.334
Rasmus Nilsson, Thomas Næss-Andresen, Tor Åge Myklebust, Tomm Bernklev, Hege Kersten, Erik Skaaheim Haug

Objectives

To prospectively analyse the associations between pre-diagnostic levels of anxiety and depression and patient-reported urinary and sexual adverse effects after radical prostatectomy in a population-based setting.

Patients and Methods

In three Norwegian county hospitals, men referred with a suspicion of prostate cancer were asked to fill out a patient-reported outcome measurement (PROM) questionnaire prior to prostate biopsy. Those who later underwent radical prostatectomy were stratified into three distress groups according to their Hopkins Symptom Checklist 5-score. Additional PROM questionnaires, including the EPIC-26 to measure adverse effects, were collected at 6 and 12 months postoperatively. Multivariable mixed models were estimated and post hoc pairwise comparisons performed to explore differences in adverse effects between distress groups.

Results

A total of 416 men were included at baseline and of those, 365 (88%) returned questionnaires at 6 months and 360 (87%) at 12 months. After adjusting for confounders, men with high distress at baseline had worse urinary incontinence domain score (58.9 vs. 66.8, p = 0.028), more urinary bother (64.7 vs. 73.6, p = 0.04) and a higher risk of using incontinence pads (70.6% vs. 54.2%, p = 0.034) at 6 months than those with low distress. There was no difference in the sexual domain scores between distress groups postoperatively, but the high-distress group expressed more sexual bother (24.9 vs. 37.5, p = 0.015) and the intermediate-distress group had a greater probability of using sexual medications or devices (63.8% vs. 50.0%, p = 0.015) than the low-distress group at 6 months. At 12 months scores generally improved slightly and differences between distress groups were less evident.

Conclusion

Men with higher levels of anxiety and depression before prostate biopsy report more urinary and sexual adverse effects after radical prostatectomy. This should be considered both in treatment decision-making and during follow-up after radical prostatectomy.

在挪威的三家县级医院,怀疑患有前列腺癌的男性被要求在前列腺活检前填写一份患者报告结果测量(PROM)问卷。后来接受根治性前列腺切除术的患者根据其霍普金斯症状清单5分被分为三个痛苦组。术后6个月和12个月还收集了其他PROM问卷,包括用于测量不良反应的EPIC-26。我们估算了多变量混合模型,并进行了事后配对比较,以探讨不同窘迫组之间不良反应的差异。在对混杂因素进行调整后,基线时窘迫程度较高的男性与窘迫程度较低的男性相比,在6个月时尿失禁领域得分较低(58.9 vs. 66.8,p = 0.028),排尿困扰较多(64.7 vs. 73.6,p = 0.04),使用尿失禁垫的风险较高(70.6% vs. 54.2%,p = 0.034)。术后各困扰组在性领域的得分没有差异,但在 6 个月时,高困扰组比低困扰组表达了更多的性困扰(24.9 vs. 37.5,p = 0.015),中度困扰组比低度困扰组使用性药物或性器具的概率更高(63.8% vs. 50.0%,p = 0.015)。在12个月时,得分普遍略有提高,而压力组之间的差异则不太明显。在前列腺活检前焦虑和抑郁程度较高的男性在前列腺根治术后会出现更多的泌尿和性方面的不良反应。在前列腺癌根治术后的治疗决策和随访过程中都应考虑到这一点。
{"title":"The association between pre-diagnostic levels of psychological distress and adverse effects after radical prostatectomy","authors":"Rasmus Nilsson,&nbsp;Thomas Næss-Andresen,&nbsp;Tor Åge Myklebust,&nbsp;Tomm Bernklev,&nbsp;Hege Kersten,&nbsp;Erik Skaaheim Haug","doi":"10.1002/bco2.334","DOIUrl":"10.1002/bco2.334","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To prospectively analyse the associations between pre-diagnostic levels of anxiety and depression and patient-reported urinary and sexual adverse effects after radical prostatectomy in a population-based setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>In three Norwegian county hospitals, men referred with a suspicion of prostate cancer were asked to fill out a patient-reported outcome measurement (PROM) questionnaire prior to prostate biopsy. Those who later underwent radical prostatectomy were stratified into three distress groups according to their Hopkins Symptom Checklist 5-score. Additional PROM questionnaires, including the EPIC-26 to measure adverse effects, were collected at 6 and 12 months postoperatively. Multivariable mixed models were estimated and post hoc pairwise comparisons performed to explore differences in adverse effects between distress groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 416 men were included at baseline and of those, 365 (88%) returned questionnaires at 6 months and 360 (87%) at 12 months. After adjusting for confounders, men with high distress at baseline had worse urinary incontinence domain score (58.9 vs. 66.8, <i>p</i> = 0.028), more urinary bother (64.7 vs. 73.6, <i>p</i> = 0.04) and a higher risk of using incontinence pads (70.6% vs. 54.2%, <i>p</i> = 0.034) at 6 months than those with low distress. There was no difference in the sexual domain scores between distress groups postoperatively, but the high-distress group expressed more sexual bother (24.9 vs. 37.5, <i>p</i> = 0.015) and the intermediate-distress group had a greater probability of using sexual medications or devices (63.8% vs. 50.0%, <i>p</i> = 0.015) than the low-distress group at 6 months. At 12 months scores generally improved slightly and differences between distress groups were less evident.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Men with higher levels of anxiety and depression before prostate biopsy report more urinary and sexual adverse effects after radical prostatectomy. This should be considered both in treatment decision-making and during follow-up after radical prostatectomy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 5","pages":"502-511"},"PeriodicalIF":0.0,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.334","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140435148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thoughts on ‘Efficacy of RestoreX after prostatectomy: open-label phase of an RCT’ 关于 "前列腺切除术后 RestoreX 的疗效:RCT 的开放标签阶段 "的想法
Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-02-22 DOI: 10.1002/bco2.320
Mustafa Ganijee, Rasi Mizori, Awab Ahmad, Mirza Hashim Ahmad, Malik Takreem Ahmad
<p>We congratulate Zganjar et al. on their evaluation of the effects of RestoreX penile traction therapy following post-prostatectomy.<span><sup>1</sup></span> This single-centre, randomised trial offers valuable insights into the impact of RestoreX on a common yet under-researched complication: reduced penile length. Given that prostate cancer is the most common cancer worldwide,<span><sup>2</sup></span> and prostatectomy remains the definitive treatment of choice, this study addresses some important concerns related to post-prostatectomy complications and potential management strategies.</p><p>However, several factors might constrain the generalisability of these findings. Firstly, the study's narrow demographic scope and its single-centre design mean that lack of patient diversity is a limitation. With the inclusion of 82 men, only 45 of whom there is 9-month data available for, extrapolating these results to the broader population is challenging. A single-centre study inherently reflects the patients within that specific centre and does not fully reflect the diverse demographics of patients affected by this complication globally. Post-prostatectomy complications are a pervasive issue, affecting a myriad of patient demographics worldwide,<span><sup>3</sup></span> and so this underscores the importance of research encompassing a broader range of demographics.</p><p>We also noted the significant dropout rate given the study's limited participant pool. With 45 participants out of an initial 82, this indicates a dropout rate of more than 45% of participants, further restricting the data's generalisability. Such significant dropout rates can introduce biases, and it is therefore essential to understand the reasons for these dropouts, as these may reveal potential challenges associated with RestoreX. The small sample size inherently diminishes the study's power, and this impacts the interpretation and subsequent conclusions.<span><sup>4</sup></span></p><p>Furthermore, the study monitors outcomes up to 9 months for the 45 men who completed the whole study. Although these findings are promising, the ramifications of a prostatectomy and the trajectory of post-operative recovery can span years.<span><sup>5</sup></span> A longer follow-up would offer deeper insights into RestoreX's long-term effects and reveal any latent side effects that might not manifest during shorter usage periods. Such comprehensive data would allow both patients and healthcare providers to have a holistic understanding of the medications, encompassing their prolonged effects and potential side effects.</p><p>To conclude, while Zganjar et al. study sheds light on the benefits of RestoreX treatment on penile length decrease, further studies should focus on including patients from a broader demographic to represent the diverse populations best that this complication affects. We urge further exploration into the reasons behind more than 45% of participants in the study dropping out an
我们祝贺Zganjar等人对前列腺切除术后RestoreX阴茎牵引疗法的效果进行了评估1。这项单中心随机试验就RestoreX对一种常见但研究不足的并发症--阴茎长度缩短--的影响提供了有价值的见解。鉴于前列腺癌是全球最常见的癌症2 ,而前列腺切除术仍是最终的治疗选择,本研究探讨了与前列腺切除术后并发症相关的一些重要问题以及潜在的管理策略。首先,这项研究的人口统计范围较窄,而且是单中心设计,这意味着患者缺乏多样性是一个限制因素。研究共纳入了 82 名男性患者,其中只有 45 名患者有 9 个月的数据,因此将这些结果推广到更广泛的人群中具有挑战性。单个中心的研究本质上反映的是该中心的患者情况,并不能完全反映全球受这种并发症影响的患者的人口统计学特征。前列腺切除术后并发症是一个普遍存在的问题,影响着全球众多患者的人口结构3,因此这凸显了研究涵盖更广泛人口结构的重要性。在最初的 82 名参与者中,有 45 人退出了研究,这表明退出率超过了 45%,进一步限制了数据的普遍性。如此高的辍学率可能会造成偏差,因此了解辍学原因至关重要,因为这可能会揭示与 RestoreX 相关的潜在挑战。4 此外,该研究对完成整个研究的 45 名男性进行了长达 9 个月的结果监测。尽管这些研究结果令人鼓舞,但前列腺切除术的影响和术后恢复的轨迹可能长达数年。5 更长时间的随访将有助于深入了解 RestoreX 的长期效果,并揭示在较短使用期内可能无法显现的任何潜在副作用。总之,虽然 Zganjar 等人的研究揭示了 RestoreX 治疗对阴茎长度减少的益处,但进一步的研究应侧重于纳入更广泛人群中的患者,以最好地代表这一并发症所影响的不同人群。我们敦促进一步探讨超过 45% 的参与者退出研究的原因,以及如何处理这一原因以提高依从性,尤其是在现实世界中。最后,我们希望未来的研究能对 RestoreX 的效果进行更长时间的探索,从而深入了解其长期效果以及任何相关并发症/副作用,让患者和医疗从业人员有所了解。第一作者 Mustafa Ganijee 博士谨此声明,我是一名全科医生,专攻男性性健康,尤其是勃起功能障碍和早泄的私人治疗。因此,本信中的观点和批判性评论是根据我的临床经验撰写的。不过,这种个人兴趣并不会影响我专业观点的完整性或客观性。以下观点是基于科学证据和公正的专业判断提出的。此外,也没有任何利益冲突或经济利益直接或间接影响到这封致编辑的信。
{"title":"Thoughts on ‘Efficacy of RestoreX after prostatectomy: open-label phase of an RCT’","authors":"Mustafa Ganijee,&nbsp;Rasi Mizori,&nbsp;Awab Ahmad,&nbsp;Mirza Hashim Ahmad,&nbsp;Malik Takreem Ahmad","doi":"10.1002/bco2.320","DOIUrl":"10.1002/bco2.320","url":null,"abstract":"&lt;p&gt;We congratulate Zganjar et al. on their evaluation of the effects of RestoreX penile traction therapy following post-prostatectomy.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; This single-centre, randomised trial offers valuable insights into the impact of RestoreX on a common yet under-researched complication: reduced penile length. Given that prostate cancer is the most common cancer worldwide,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; and prostatectomy remains the definitive treatment of choice, this study addresses some important concerns related to post-prostatectomy complications and potential management strategies.&lt;/p&gt;&lt;p&gt;However, several factors might constrain the generalisability of these findings. Firstly, the study's narrow demographic scope and its single-centre design mean that lack of patient diversity is a limitation. With the inclusion of 82 men, only 45 of whom there is 9-month data available for, extrapolating these results to the broader population is challenging. A single-centre study inherently reflects the patients within that specific centre and does not fully reflect the diverse demographics of patients affected by this complication globally. Post-prostatectomy complications are a pervasive issue, affecting a myriad of patient demographics worldwide,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; and so this underscores the importance of research encompassing a broader range of demographics.&lt;/p&gt;&lt;p&gt;We also noted the significant dropout rate given the study's limited participant pool. With 45 participants out of an initial 82, this indicates a dropout rate of more than 45% of participants, further restricting the data's generalisability. Such significant dropout rates can introduce biases, and it is therefore essential to understand the reasons for these dropouts, as these may reveal potential challenges associated with RestoreX. The small sample size inherently diminishes the study's power, and this impacts the interpretation and subsequent conclusions.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Furthermore, the study monitors outcomes up to 9 months for the 45 men who completed the whole study. Although these findings are promising, the ramifications of a prostatectomy and the trajectory of post-operative recovery can span years.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; A longer follow-up would offer deeper insights into RestoreX's long-term effects and reveal any latent side effects that might not manifest during shorter usage periods. Such comprehensive data would allow both patients and healthcare providers to have a holistic understanding of the medications, encompassing their prolonged effects and potential side effects.&lt;/p&gt;&lt;p&gt;To conclude, while Zganjar et al. study sheds light on the benefits of RestoreX treatment on penile length decrease, further studies should focus on including patients from a broader demographic to represent the diverse populations best that this complication affects. We urge further exploration into the reasons behind more than 45% of participants in the study dropping out an","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 4","pages":"515-516"},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.320","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140442137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
‘Staying Hot’: Investigating the influence of overnight conditions on the penile skin temperature during male sexual arousal—A novel methodology for nocturnal erection detection 保持热度调查夜间条件对男性性兴奋时阴茎皮肤温度的影响--夜间勃起检测的新方法
Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-02-22 DOI: 10.1002/bco2.328
Hille J. Torenvlied, Evelien Trip, Wouter Olthuis, Loes I. Segerink, Jack J. H. Beck

Objective

The objective of this study is to assess the impact of overnight environmental conditions on erectile penile temperature within a controlled setting, with the aim of investigating the feasibility of using temperature measurements for nocturnal erection detection in erectile dysfunction diagnostics.

Subjects/patients and methods

We conducted a proof-of-concept study involving 10 healthy male participants aged 20 to 25. The study was carried out at the Department of Urology, St. Antonius Ziekenhuis, the Netherlands. Penile temperature thermistor measurements were taken during visually aroused erections of participants in naked state and in simulated overnight condition (underwear and blankets). Main outcome variables were peak and baseline temperature during erectile periods. To minimize the impact of differences in erectile strength and duration between consecutive measurements, we applied randomization to the order of the environmental conditions.

Results

We observed a significant increase in penile temperature during erection in both the naked (p < 0.01) and simulated overnight condition (p < 0.01). The mean temperature increase was 1.70 and 0.67°C, respectively. While penile temperature returned to baseline immediately after naked erections, the ‘Staying Hot effect’ was noted in the simulated overnight condition measurements, where the temperature remained elevated at peak temperature for the entire 30-min period following the erection.

Conclusions

The findings from this study indicate that the penile temperature not only significantly increases during naked sexual arousal but is also detectable under simulated overnight conditions. This underscores the potential of using temperature measurements for nocturnal erection detection, representing a crucial initial step in developing a modernized, non-invasive sensor system for ambulatory erectile dysfunction diagnostics. Further research, including an overnight study, is needed to gain insights into the feasibility of utilizing penile temperature measurements for nocturnal erection detection and to assess the impact of the ‘Staying Hot effect’ on subsequent erection detection.

本研究的目的是在受控环境下评估夜间环境条件对阴茎勃起温度的影响,从而研究在勃起功能障碍诊断中使用温度测量检测夜间勃起的可行性。这项研究在荷兰圣安东尼斯泌尿科进行。阴茎温度热敏电阻测量是在参与者裸体和模拟过夜状态(内裤和毯子)下视觉唤醒勃起时进行的。主要结果变量为勃起时的峰值温度和基线温度。为了尽量减少连续测量之间勃起强度和持续时间差异的影响,我们对环境条件的先后顺序进行了随机化。平均温度分别上升了 1.70°C 和 0.67°C。裸体勃起后阴茎温度立即恢复到基线,而模拟过夜条件下的测量则出现了 "持续高温效应",即在勃起后的整个 30 分钟内,阴茎温度都保持在峰值温度。这项研究结果表明,阴茎温度不仅在裸体性唤起时明显升高,而且在模拟夜间条件下也能检测到。这突出了利用温度测量进行夜间勃起检测的潜力,为开发用于非卧床勃起功能障碍诊断的现代化无创传感器系统迈出了关键的第一步。要深入了解利用阴茎温度测量进行夜间勃起检测的可行性,并评估 "保持热度效应 "对后续勃起检测的影响,还需要开展进一步的研究,包括通宵研究。
{"title":"‘Staying Hot’: Investigating the influence of overnight conditions on the penile skin temperature during male sexual arousal—A novel methodology for nocturnal erection detection","authors":"Hille J. Torenvlied,&nbsp;Evelien Trip,&nbsp;Wouter Olthuis,&nbsp;Loes I. Segerink,&nbsp;Jack J. H. Beck","doi":"10.1002/bco2.328","DOIUrl":"10.1002/bco2.328","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study is to assess the impact of overnight environmental conditions on erectile penile temperature within a controlled setting, with the aim of investigating the feasibility of using temperature measurements for nocturnal erection detection in erectile dysfunction diagnostics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Subjects/patients and methods</h3>\u0000 \u0000 <p>We conducted a proof-of-concept study involving 10 healthy male participants aged 20 to 25. The study was carried out at the Department of Urology, St. Antonius Ziekenhuis, the Netherlands. Penile temperature thermistor measurements were taken during visually aroused erections of participants in naked state and in simulated overnight condition (underwear and blankets). Main outcome variables were peak and baseline temperature during erectile periods. To minimize the impact of differences in erectile strength and duration between consecutive measurements, we applied randomization to the order of the environmental conditions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We observed a significant increase in penile temperature during erection in both the naked (<i>p</i> &lt; 0.01) and simulated overnight condition (<i>p</i> &lt; 0.01). The mean temperature increase was 1.70 and 0.67<i>°</i>C, respectively. While penile temperature returned to baseline immediately after naked erections, the ‘Staying Hot effect’ was noted in the simulated overnight condition measurements, where the temperature remained elevated at peak temperature for the entire 30-min period following the erection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The findings from this study indicate that the penile temperature not only significantly increases during naked sexual arousal but is also detectable under simulated overnight conditions. This underscores the potential of using temperature measurements for nocturnal erection detection, representing a crucial initial step in developing a modernized, non-invasive sensor system for ambulatory erectile dysfunction diagnostics. Further research, including an overnight study, is needed to gain insights into the feasibility of utilizing penile temperature measurements for nocturnal erection detection and to assess the impact of the ‘Staying Hot effect’ on subsequent erection detection.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 4","pages":"439-446"},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.328","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140440490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BJUI compass
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1